Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Net Margin (2016 - 2025)

Spero Therapeutics' Net Margin history spans 10 years, with the latest figure at 67.03% for Q4 2025.

  • For Q4 2025, Net Margin rose 3009011.0% year-over-year to 67.03%; the TTM value through Dec 2025 reached 12.21%, up 27976.0%, while the annual FY2025 figure was 18.21%, 1722333.0% up from the prior year.
  • Net Margin reached 67.03% in Q4 2025 per SPRO's latest filing, up from 135.69% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 220.43% in Q4 2021 to a low of 30023.08% in Q4 2024.
  • Average Net Margin over 5 years is 2861.78%, with a median of 250.26% recorded in 2021.
  • Peak YoY movement for Net Margin: soared 3518228bps in 2021, then crashed -3009548bps in 2024.
  • A 5-year view of Net Margin shows it stood at 220.43% in 2021, then dropped by -14bps to 189.0% in 2022, then crashed by -62bps to 72.4% in 2023, then crashed by -41568bps to 30023.08% in 2024, then surged by 100bps to 67.03% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Net Margin are 67.03% (Q4 2025), 135.69% (Q3 2025), and 14.44% (Q2 2025).